Advaxis, Inc. (ADXS): Earnings News

ADXS – Net loss for the first quarter ended January 31, 2018 was $20.5 million or $0.49 per share.


Key Facts Surrounding This News Item


  • ADXS had a POWR Rating of D (Sell) coming into today.
  • ADXS was 12.42% above its 10-Day Moving Average coming into today.
  • ADXS was -1.03% below its 20-Day Moving Average coming into today.
  • ADXS was -17.41% below its 50-Day Moving Average coming into today.
  • ADXS was -24.99% below its 100-Day Moving Average coming into today.
  • ADXS was -52.24% below its 200-Day Moving Average coming into today.
  • ADXS had returned -22.54% year-to-date leading up to today’s news, versus a +4.50% return from the benchmark S&P 500 during the same period.

More Info About Advaxis, Inc. (ADXS)


Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey. View our full ADXS ticker page with ratings, news, and more.

ADXS at a Glance

ADXS Current POWR Rating™
Overall POWR Rating™
ADXS Current Price $0.24 36.84%
More ADXS Ratings, Data, and News

ADXS Price Reaction

The day of this event (Mar. 12, 2018)
ADXS Closing Price$2.21 0.45%
ADXS Volume1,913,800
140.52% from avg
Leading up to this event
ADXS 1-mo return20.58%
After this event
ADXS 1-day return12.82%
ADXS 3-day return8.37%
ADXS 5-day return7.32%

ADXS Price Chart


The Top Stocks For 2019

More Advaxis, Inc. (ADXS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ADXS News
Page generated in 0.9436 seconds.